DALLAS, April 8, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "Liver Cirrhosis and Fibrosis - Pipeline Review, H1 2015" to its store. This reports provides an overview of the Liver Cirrhosis and Fibrosis therapeutic pipeline.
Cirrhosis is a complication of liver disease which involves loss of liver cells and irreversible scarring of the liver. Hepatitis C, fatty liver, and alcohol abuse are the most common causes of cirrhosis of the liver in the U.S., but anything that damages the liver can cause cirrhosis. Liver fibrosis is the scarring process that represents the liver's response to injury. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation. Cirrhosis is always developed from fibrosis. Although, fibrosis and cirrhosis are different, they are closely related. They are two distinguished pathological conditions.
The report "Liver Cirrhosis and Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Liver Cirrhosis and Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and Fibrosis and special features on late-stage and discontinued projects.
Companies discussed in this Liver Cirrhosis - Pipeline Review, H1 2015 report include Alfa Wassermann S.p.A, Conatus Pharmaceuticals Inc., Digna Biotech, S.L., Galectin Therapeutics, Inc., Gilead Sciences, Inc., GNI Group Ltd., Pacific Therapeutics Ltd., PharmaIN Corporation, Pharmicell Co., Ltd., S-Evans Biosciences, Inc., Stelic Institute & Co., Stempeutics Research Private Limited.
Drugs profiles discussed in this report includes (sofosbuvir + GS-5816), Cell Therapy for Liver Cirrhosis, DB-027, DB-036, emricasan, F-351, GR-MD-01, GR-MD-02, GXHPC-1, Livercellgram, Monoclonal Antibodies to Antagonize Transforming Growth Factor Beta 1 for HCV associated Liver Cirrhosis, PTL-303, Px-104, rifaximin, simtuzumab, Stem Cell Therapy for Liver Cirrhosis, Stem Cell Therapy for Liver Cirrhosis, Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders, Stem Cell Therapy for Rheumatoid Arthritis and Liver Cirrhosis, Stempeucel, STNM-04, thrombopoietin, Undisclosed Peptide for Liver Cirrhosis. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=347015 . (This is a premium report priced at US$2000 for a single user License.)
Companies discussed in this Liver Fibrosis - Pipeline Review, H1 2015 report include Advinus Therapeutics Ltd., Angion Biomedica Corp., BerGenBio AS, BiOrion Technologies B.V., Celgene Corporation, Digna Biotech, S.L., FibroGen, Inc., Galectin Therapeutics, Inc., Genfit SA, GenKyoTex S.A., Gilead Sciences, Inc., GNI Group Ltd., La Jolla Pharmaceutical Company, LG Life Sciences, Ltd., Nitto Denko Corporation, Pharmaxis Limited, Promedior, Inc., Promethera Biosciences S.A., ProMetic Life Sciences Inc., RXi Pharmaceuticals Corporation, TCM Biotech International Corp, Vascular Biogenics Ltd., Virobay Inc.,
Drugs profiles discussed in this report includes ANG-3281, ANG-3298, ANG-4011, BGB-324, BOT-162, BOT-191, CC-539, CC-90001, CIGB-500, CT-140, DB-036, DCBBO-1202, disitertide, Drugs to Inhibit NADPH Oxidase for Influenza and Liver Fibrosis, F-351, FG-3019, GCS-100, GFT-505, GKT-137831, GKT-901, GM-CT-01, GM-CT-02, GR-MD-01, GR-MD-02, HepaStem, KW-0, LC-280126, LJPC-201, melittin, ND-L02s0201, NPLC-0393, P-17, PBI-4050, PRI-724, PRM-151, PXS-4728A, PXS-5033A, RXI-209, simtuzumab, Small Molecule for Liver Fibrosis, Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis, Stem Cell Therapy for Liver Fibrosis and Liver Diseases, Synthetic Peptide to Inhibit RSK for Fibrosis and Oncology, TCM-808FB, TGFTX-4 Program, VB-201, VBY-376, VBY-825. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=347019 . (This is a premium report priced at US$2000 for a single user License.)
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Featured News & Press Releases cover by this report includes: Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting; Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting; Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension; Jul 23, 2012: Galectin Therapeutics Receives US Patent for Potential Treatment for Chronic Liver Disease with Fibrosis And Cirrhosis; Jan 20, 2011: Stempeutics Research's Stempeucel LC Recieves DCGI Clearance To Start Phase II Clinical Trial For Liver Cirrhosis; Nov 07, 2007: China Patent and Trademark Office Grants Patent for F351, GNI's Key Therapeutic Product for Liver Disease.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Liver fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Liver fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
SOURCE RnR Market Research